Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

82.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Lancet.
Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Skyler JS.
| Jul 30, 2011
83.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Lancet.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG, Lenhard J.
| Aug 6, 2011
84.

Myxoma, dyspnoea, tinnitus, scoliosis, and alopecia.

Lancet.
Rajab TK, Shekar P, Falk RH.
| Apr 16, 2011
85.

Social accountability in health professionals' training.

Lancet.
Wen LS, Greysen SR, Keszthelyi D, Bracero J, de Roos PD.
| Dec 3, 2011
88.

EMBRACE, eribulin, and new realities of advanced breast cancer.

Lancet.
Lin NU, Burstein HJ.
| Mar 12, 2011
89.

BLISS! Lupus learns its lessons.

Lancet.
Stone JH.
| Feb 26, 2011
90.

Five complementary interventions to slow cholera: Haiti.

Lancet.
Ivers LC, Farmer P, Almazor CP, Léandre F.
| Dec 18, 2010
91.

A new standard of care in newly diagnosed multiple myeloma.

Lancet.
Richardson PG.
| Dec 18, 2010
92.

Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.

Lancet.
Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, Murray M, Atwood SS, Mitnick CD.
| Jan 8, 2011
93.

Cholera's western front.

Lancet.
Harris JB, Larocque RC, Charles RC, Mazumder RN, Khan AI, Bardhan PK.
| Dec 11, 2010
94.

Time for a bold new vision at the Stop TB Partnership.

Lancet.
Keshavjee S, Girard F, Harrington M, Farmer PE.
| Oct 16, 2010
95.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Lancet.
Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.
| Oct 16, 2010
96.

A complement to kidney disease: CFHR5 nephropathy.

Lancet.
Karumanchi SA, Thadhani R.
| Sep 4, 2010
97.

Childhood cancer survivors: stillbirth and neonatal death.

Lancet.
Viswanathan AN.
| Aug 21, 2010
98.

Expansion of cancer care and control in countries of low and middle income: a call to action.

Lancet.
Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR.
| Oct 2, 2010
99.

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.

Lancet.
Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ.
| Jul 31, 2010
100.

Untreated HIV: harmful even at high CD4 cell counts.

Lancet.
Bassett IV, Sax PE.
| Jul 31, 2010